On January 10, 2025, the US Court of Appeals for the Federal Circuit issued a precedential opinion in Novartis Pharmaceuticals Corp. v. Torrent ...

The Federal Circuit has issued a precedential decision reversing a lower court’s decision that certain claims of Novartis’s ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit ...

Novartis (NVS) said the U.S. Court of Appeals has upheld the company's U.S. combination patent for its blockbuster cardiac drug Entresto. Read more here.

(RTTNews) - Swiss drug major Novartis (NVS) Monday announced that the US Court of Appeals for the Federal Circuit or CAFC has decided to upheld the validity of the Entresto (sacubitril/valsartan) ...

Doses were titrated over 6 months (daily maximums, 160 mg and 10 mg, respectively), and agents from other drug classes were ... treatment previously. Valsartan's manufacturer sponsored the trial.

The Swiss pharmaceutical company said the court affirmed the validity of its patent on Entresto and combinations of sacubitril and valsartan ... It added that were no generic versions of Entresto ...

Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the ...

Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent. We ...

MSN Pharma was given FDA approval for its Entresto (sacubitril and valsartan) generic on 24th July, prompting a lawsuit from Novartis claiming patent infringement and seeking a preliminary ...